Showing 3501-3510 of 3714 results for "".
Annual Meeting Highlights; Ortho Derm's New Cash Pay Model
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-annual-meeting-highlights-ortho-derm-s-new-cash-pay-model/19579/The annual meeting of the American Academy of Dermatology features updates in medical, surgical, and cosmetic dermatology. Practical Dermatology Chief medical editor Dr. Neal Bhatia highlighted the breadth of coverage at the meeting. DermTube caught up with multiple presenters who shared pearls fromUpdates from CSF 2017
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-updates-from-csf-2017/18371/Dermatologists and core cosmetic physicians shared new insights and reviewed the developments in clinical and cosmetic dermatology at the ninth annual Cosmetic Surgery Forum in Las Vegas. Matthew Zirwas, MD addressed interest in oral supplements to support skin health. Neurotoxin pioneer Nick Lowe,eRelevance Uncovers Marketing Truths, EADV Data, Primetime for Botox
https://practicaldermatology.com/series/dermwire-tv/erelevance-uncovers-marketing-truths-eadv-data-primetime-for-botox/18429/The State of Aesthetic Healthcare Marketing 2017 from eRelevance shows that nearly 60 percent of aesthetic physicians say they either don't see results from their marketing initiatives or aren't able to measure results. Data presented at the annual meeting of the European Academy of Dermatology andRhofade Approved, Sun Leaves Acne Behind, Radiesse Turns 10
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-rhofade-approved-sun-leaves-acne-behind-radiesse-turns-10/18552/The FDA has approved Allergan's Rhofade (Oxymetazoline 1%) cream for the topical treatment of persistent facial erythema associated with rosacea in adults. New research from Olay in collaboration with personal genetics company 23andMe shows that taking care of the skin may be the key to looking upRisk In Your Portfolio
https://practicaldermatology.com/topics/practice-management/risk-in-your-portfolio/18588/Do you know your risk score? Physicians must understand their personal tolerance for risk as well as the level of risk in their current portfolios. If there is a mismatch, how do you rectify the disconnect. Bob Peelman, CFP, of OJM Group, explains. ABOUT THE AUTHORDermWireTV: Spevigo for GPP; Derms on Acne Experience; IFPA Takes PsO to the Gaming World; La Roche-Posay at the US Open
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-spevigo-for-gpp-derms-on-acne-experience-ifpa-takes-pso-to-the-gaming-world-la-roche-posay-at-the-us-open/20136/Boehringer Ingelheim’s Spevigo is the first FDA-approved treatment option for generalized pustular psoriasis (GPP) flares in adults. Spesolimab is a novel, selective antibody that blocks the activation of the interleukin-36 receptor. Dermatologists, dermatology physician assistants, and dermatologyDermWireTV: COVID-19 Loans, Taltz for Peds, Finacea Returns
https://practicaldermatology.com/topics/practice-management/dermwiretv-covid-19-loans-taltz-for-peds-finacea-returns/19808/SBA Loans and Paycheck Protection Program (PPP) loans for practices impacted by the coronavirus pandemic are among the options addressed in a new video series, “Coping with COVID-19.” Eli Lilly and Company's Taltz is now approved to manage moderate to severe plaque psoriasis in pediatric patients aRhatigan to Merz, MOC Dissatisfaction, Syneron-Candela Sale
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-rhatigan-to-merz-moc-dissatisfaction-syneron-candela-sale/18485/Industry veteran Bob Rhatigan is the new President and Chief Executive Officer of Merz North America. Patrick Urban is new Chief Commercial Officer. In a transaction valued at approximately $397 million, an affiliate of funds advised by Apax Partners will acquire all of the outstanding shares of SySuperficial Radiation for Keloids: SRT-100 in Practice
https://practicaldermatology.com/topics/skin-cancer-photoprotection/superficial-radiation-for-keloids-srt-100-in-practice/19040/Keloids are common. Certain patients, especially patients of color, are more prone to the development of keloids in certain locations, especially areas such as the chest, back, and other areas. Most studies that show that keloids can occur in up to 90 percent of cases when they're excised. The use oSeparating Fact from Fiction: The Realities of CKD-aP
https://practicaldermatology.com/programs/cme/separating-fact-from-fiction-the-realities-of-ckd-ap/14964/Separate facts from fiction in CKD-aP! Our experts tackle this often overlooked condition and discuss ways to improve your patients’ lives.